Literature DB >> 2688428

Fluorouracil Filtering Surgery Study one-year follow-up. The Fluorouracil Filtering Surgery Study Group.

.   

Abstract

Two hundred thirteen patients participated in the Fluorouracil Filtering Surgery Study, a randomized clinical trial, to determine the efficacy and safety of subconjunctivally injected 5-fluorouracil after filtering surgery in eyes with poor prognoses. Twenty-eight (27%) of the 105 eyes in the 5-fluorouracil group and 54 (50%) of the 108 eyes in the standard group were classified as failures, defined by reoperation for control of intraocular pressure during the first year or an intraocular pressure greater than 21 mm Hg at the one-year visit (P = .0007, Mantel-Haenszel chi-square). Corneal epithelial toxicity and transient visual acuity loss were more common in the 5-fluorouracil group (P less than .001, chi-square); however, the visual acuities and the mean visual field sensitivities were not significantly different at one year. We recommend the use of subconjunctivally injected 5-fluorouracil after trabeculectomy in eyes with uncontrolled glaucoma and poor prognoses, specifically after previous cataract extraction or unsuccessful filtering surgery.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688428     DOI: 10.1016/0002-9394(89)90853-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  38 in total

1.  Trypan blue identifies antimetabolite treatment area in trabeculectomy.

Authors:  P R Healey; J G Crowston
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

2.  Suprachoroidal implant surgery in intractable glaucoma.

Authors:  Melis Palamar; Halil Ates; Zafer Oztas; Emil Yusifov
Journal:  Jpn J Ophthalmol       Date:  2011-05-27       Impact factor: 2.447

3.  Identification and Correction of Restrictive Strabismus After Pterygium Excision Surgery.

Authors:  Sally L Baxter; Brian J Nguyen; Michael Kinori; Don O Kikkawa; Shira L Robbins; David B Granet
Journal:  Am J Ophthalmol       Date:  2019-02-14       Impact factor: 5.258

4.  The role of needle revision and 5-fluorouracil application over the filtration site in the management of bleb failure after trabeculectomy: a prospective study.

Authors:  Ismet Durak; Zeynep Ozbek; Aylin Yaman; Meltem Soylev; Güray Cingil
Journal:  Doc Ophthalmol       Date:  2003-03       Impact factor: 2.379

5.  Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up.

Authors:  Steven J Gedde; Joyce C Schiffman; William J Feuer; Leon W Herndon; James D Brandt; Donald L Budenz
Journal:  Am J Ophthalmol       Date:  2012-01-15       Impact factor: 5.258

6.  Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up.

Authors:  Steven J Gedde; Leon W Herndon; James D Brandt; Donald L Budenz; William J Feuer; Joyce C Schiffman
Journal:  Am J Ophthalmol       Date:  2012-01-14       Impact factor: 5.258

7.  Five year results of viscocanalostomy.

Authors:  T Shaarawy; C Nguyen; C Schnyder; A Mermoud
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

8.  A randomised, prospective study comparing trabeculectomy with viscocanalostomy with adjunctive antimetabolite usage for the management of open angle glaucoma uncontrolled by medical therapy.

Authors:  D P S O'Brart; M Shiew; B Edmunds
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

9.  SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery.

Authors:  Li-Fong Seet; Roseline Su; V A Barathi; Wing Sum Lee; Rebekah Poh; Yee Meng Heng; Ed Manser; Eranga N Vithana; Tin Aung; Matt Weaver; E Helene Sage; Tina T Wong
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

10.  Growth inhibition of human Tenon's capsule fibroblasts and rabbit dermal fibroblasts with non-carcinogenic N-alkylated anthracyclines.

Authors:  U H Steinhorst; E P Chen; S F Freedman; R Machemer; D L Hatchell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-06       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.